Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status

Abstract

Background Management of early-stage breast cancer in young women with mutations in BRCA1 or BRCA2 remains controversial. This study assessed the long-term risks of ipsilateral and contralateral breast cancer in a cohort of young women who underwent breast-conserving surgery followed by radiotherapy. Methods Between 1975 and 1998, 290 women with breast cancer diagnosed at age 42 years or younger underwent lumpectomy followed by radiotherapy at our hospital. We recruited 127 of these women for complete sequencing of BRCA1 and BRCA2. Demographic, clinical, pathological, and outcome data were recorded. The primary endpoints were rates of ipsilateral and contralateral breast cancer, in relation to germline BRCA1/2 status. Findings 105 women were classified as having sporadic disease (94 with wild-type or known polymorphisms and 11 with variants of unclear significance) and 22 as having genetic predisposition (deleterious mutations in BRCA1 [15] or BRCA2 [seven]). At 12 years of follow-up, the genetic group had significantly higher rates of ipsilateral (49% vs 21%, p=0.007) and contralateral events (42% vs 9%, p=0.001) than the sporadic group. The majority of events were classified as second primary tumours. No patient in the genetic group had undergone oophorectomy or was taking prophylactic agents such as tamoxifen. Interpretation Patients with germline mutations in BRCA1 or BRCA2 have a high risk of developing late ipsilateral and contralateral second primary tumours. With brea…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(02)08434-9

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Seynaeve, 1998, Local recurrence following lumpectomy and irradiation in familial and hereditary vs sporadic breast cancer patients, Proc ASCO, 17, 119a

Cited by

See all 307

Metadata

Authors
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., Bale, A. E., & Alvarez-Franco, M.
Affiliations
Yale University (US)
Corresponding author
Haffty, Bruce G
Venue
The Lancet
Publisher
Elsevier BV
Published
2002-04
Volume
359
Issue
9316
Pages
1471-1477
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2081943419
Cited by
307
References
32
Citations by year
2026: 4 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 13 · 2020: 11 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 12 · 2015: 14 · 2014: 11 · 2013: 12 · 2012: 20
FWCI
12.02
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
early-onset breast cancer, BRCA1, BRCA2, germline mutations, breast-conserving surgery, radiotherapy, ipsilateral breast cancer, contralateral breast cancer, second primary tumours, young women, bilateral mastectomy, chemoprophylaxis, genetic susceptibility
MeSH terms
Adult, Aged, Breast Neoplasms, Combined Modality Therapy, DNA Mutational Analysis, DNA, Neoplasm, Female, Humans, Middle Aged, Mutation, Neoplasm Recurrence, Local, Radiotherapy, Mastectomy, Segmental, Treatment Outcome, Age of Onset, Disease-Free Survival, BRCA1 Protein, BRCA2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. https://app.cochat.ai/papers/10.1016/s0140-6736(02)08434-9
The paper
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., Bale, A. E., & Alvarez-Franco, M. (2002). Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. The Lancet. https://doi.org/10.1016/s0140-6736(02)08434-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.